Drug Giant Merck Breaks Out Past New Buy Point; CME, Marathon Eye Entries

Group 1 - Nvidia's performance is positively influencing futures, with key indexes attempting to recover from recent losses [1] - Merck's stock experienced a significant increase due to a surprise win for its drug, sotatercept, in treating pulmonary hypertension [2] - CME Group and Marathon Petroleum are highlighted as strong stocks to monitor in the current market environment [1] Group 2 - Ligand Pharma's stock has surged by 88% this year, driven by its involvement in two major drugs [4] - The market is seeing a focus on stocks near buy points, including CrowdStrike and Valero, as oil refinery margins improve [4] - Merck is actively engaging in acquisitions, exemplified by its $9.2 billion deal for Cidara Therapeutics [4]